[go: up one dir, main page]

ES2126536B1 - "preparado farmaceutico para administracion intranasal y procedimientopara su produccion". - Google Patents

"preparado farmaceutico para administracion intranasal y procedimientopara su produccion".

Info

Publication number
ES2126536B1
ES2126536B1 ES09701891A ES9701891A ES2126536B1 ES 2126536 B1 ES2126536 B1 ES 2126536B1 ES 09701891 A ES09701891 A ES 09701891A ES 9701891 A ES9701891 A ES 9701891A ES 2126536 B1 ES2126536 B1 ES 2126536B1
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
procedure
production
intranasal administration
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09701891A
Other languages
English (en)
Other versions
ES2126536A1 (es
Inventor
Rie Igarashi
Mitsuko Takenaga
Hiroshi Muramatsu
Tetsuo Ebata
Yasuo Kosaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Yakuhin Kogyo KK
Fuji Yakuhin Co Ltd
Original Assignee
Fuji Yakuhin Kogyo KK
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Kogyo KK, Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Kogyo KK
Publication of ES2126536A1 publication Critical patent/ES2126536A1/es
Application granted granted Critical
Publication of ES2126536B1 publication Critical patent/ES2126536B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparado farmacéutico para administración intranasal, y procedimiento para su producción, que tiene un régimen de absorción en menores efectos irritantes. El preparado farmacéutico comprende una mezcla de una resina adsorbente en polvo y un péptido biológicamente activo provisto de efecto de fármaco con la condición de que estén secos con anterioridad o después de mezclado.
ES09701891A 1996-10-07 1997-09-05 "preparado farmaceutico para administracion intranasal y procedimientopara su produccion". Expired - Lifetime ES2126536B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8282866A JP3020141B2 (ja) 1996-10-07 1996-10-07 経鼻投与用製剤

Publications (2)

Publication Number Publication Date
ES2126536A1 ES2126536A1 (es) 1999-03-16
ES2126536B1 true ES2126536B1 (es) 1999-10-01

Family

ID=17658107

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09701891A Expired - Lifetime ES2126536B1 (es) 1996-10-07 1997-09-05 "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".

Country Status (16)

Country Link
US (1) US5948749A (es)
JP (1) JP3020141B2 (es)
KR (1) KR19980032364A (es)
CN (1) CN1180569A (es)
AU (1) AU3992697A (es)
CA (1) CA2217409A1 (es)
DE (1) DE19740733A1 (es)
DK (1) DK114797A (es)
ES (1) ES2126536B1 (es)
FI (1) FI973244A (es)
FR (1) FR2754453A1 (es)
GB (1) GB2322077A (es)
GR (1) GR970100333A (es)
IT (1) IT1295047B1 (es)
NO (1) NO974618L (es)
SE (1) SE9703133L (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE69924504T2 (de) * 1998-08-26 2006-02-16 Teijin Ltd. Pulverförmige pernasale mittel
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE341562T1 (de) * 1999-06-30 2006-10-15 Takeda Pharmaceutical Verfahren zur darstellung von lh-rh-derivaten
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
KR20150039211A (ko) 2004-08-23 2015-04-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX360812B (es) 2006-02-22 2018-11-16 Mannkind Corp Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
WO2008078730A1 (ja) * 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
EP2300083B1 (en) 2008-06-20 2013-05-22 MannKind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
SG176738A1 (en) 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
CN103638527A (zh) * 2013-12-05 2014-03-19 浙江大学 促红细胞生成素载药纳米粒及其应用
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
CN106362158A (zh) * 2015-07-25 2017-02-01 于杰 增效药物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB792544A (en) * 1956-05-07 1958-03-26 American Home Prod Therapeutic composition
JPS4917563B1 (es) * 1970-12-28 1974-05-01
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS62223131A (ja) * 1986-03-26 1987-10-01 Nitto Electric Ind Co Ltd 持続性鼻疾患治療剤
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
ATE204750T1 (de) * 1992-06-12 2001-09-15 Teijin Ltd Pharmazeutische zubereitung zur anwendung in den atemwegen
US5675031A (en) * 1992-09-10 1997-10-07 Teijin Limited 4-hydroxy-2-cyclopentenone derivatives and anticancer agent and bone formation accelerator containing the same
DE69403541T2 (de) * 1993-02-05 1997-09-25 Teijin Ltd Lacton-Verbindung und Verfahren zu ihrer Herstellung
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
AU3992697A (en) 1998-04-09
FR2754453A1 (fr) 1998-04-17
KR19980032364A (ko) 1998-07-25
NO974618L (no) 1998-04-08
JP3020141B2 (ja) 2000-03-15
NO974618D0 (no) 1997-10-06
CN1180569A (zh) 1998-05-06
DE19740733A1 (de) 1998-04-09
GB2322077A (en) 1998-08-19
ITMI972144A1 (it) 1999-03-22
FI973244A (fi) 1998-04-08
JPH10114645A (ja) 1998-05-06
IT1295047B1 (it) 1999-04-27
SE9703133D0 (sv) 1997-08-29
GR970100333A (el) 1998-06-30
SE9703133L (sv) 1998-04-08
US5948749A (en) 1999-09-07
DK114797A (da) 1998-04-08
CA2217409A1 (en) 1998-04-07
FI973244A0 (fi) 1997-08-06
GB9718690D0 (en) 1997-11-12
ES2126536A1 (es) 1999-03-16

Similar Documents

Publication Publication Date Title
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
ID23806A (id) Komposisi-komposisi farmasi untuk pemberian oral yang terdiri dari bahan aktif dan siklodekstrin
AR002009A1 (es) Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
IL138767A0 (en) Anticancer compositions
ATE188471T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
DE69637961D1 (de) Verabreichung von biologisch aktiven polypeptiden
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
AU1534699A (en) Osmotic dosage form comprising first and second coats
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
PT1123120E (pt) Formulacao medicinal em aerossol
ES2171431T3 (es) Composicion farmaceutica para liberacion controlada.
GEP20022707B (en) Biodegrading Macromers for the Controlled Release of Biologically Active Substances
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
ES2189018T3 (es) Utilizacion de polvos de polimeros o granulados de polimeros redispersables para el revestimiento de formas de administracion farmaceuticas o agroquimicas.
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990316

Kind code of ref document: A1

Effective date: 19990316

FA2A Application withdrawn

Effective date: 20030610